In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Contrast Media Manufacturers Lock Up Distribution Channels

Executive Summary

Thanks to the continued conversion of customers to non-ionic contrast media, the market for contrast agents exploded to phenomenal heights in the last decade. But with growth slowing, manufacturers are looking to cement their grip on distribution channels through big acquisitions.

You may also be interested in...



Amersham's Push for High-Value Diagnostics

Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.

CureVac Launches IPO, Adds To Big 2020 Cash Haul

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.

US FDA Finds Four More Firms Selling Unapproved COVID-19 Tests OTC, Including Stool Sample Kit

One stool sample kit and three serology tests are identified in the agency’s latest warning on OTC sales of unapproved COVID-19 tests. One of the warned firm continues offering sales of its violative product.

Related Companies

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel